AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6347921
Drug: Sulconazole nitrate
RxNorm normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulconazole nitrate cream 1%
Trial: 6347921
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate cream 2% (twice daily application)
Trial: 6347921
Drug: Sulconazole nitrate
RxNorm normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulconazole nitrate cream 1% (bid)
Trial: 31331390
Drug: Past H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past H. pylori infection (sero-negative to H. pylori IgG antibody) with atrophic gastritis
Trial: 22943685
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of mesenchymal stem cells (MSCs) [(4.9 ± 1.7) × 10(8), n = 17]
Trial: 22943685
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of mononuclear stem cells (MNCs) [(5.1 ± 2.0) × 10(8), n = 16]
Trial: 18978490
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg daily for 3 weeks, then 10 mg daily for 3 weeks
Trial: 11588522
Drug: nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine (20 mg/d)
Trial: 11588522
Drug: trandolapril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trandolapril (2 mg/d)
Trial: 2574764
Drug: Tiludronate 100
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate 100 mg daily for 6 months
Trial: 29588137
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 mg per day)
Trial: 28389801
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with fentanyl (IV PCA group)
Trial: 26268910
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg CCX140-B
Trial: 26268910
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CCX140-B
Trial: 24157585
Drug: Slow intravenous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow intravenous injection of photosensitizer during the first 15 minutes of irradiation (Group A)
Trial: 24157585
Drug: Fomentation before
RxNorm normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fomentation before photosensitizer injection and irradiation (Group B)
Trial: 24157585
Drug: Traditional injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional injection method (Control Group C)
Trial: 11561779
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide (3 x 400 mg/m2)
Trial: 9243169
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (CIT) at a dose of 0.5 g.kg‐1 body mass
Trial: 8488172
Drug: DL-cysteine 200
RxNorm normalized name: CYSTEINE, DL-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-cysteine 200 mg 4 times daily
Trial: 8488172
Drug: DL-methionine-methyl sulphonium
RxNorm normalized name: N-acetyl-methionine, DL-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-methionine-methyl sulphonium chloride (MMSC) 500 mg 4 times daily
Trial: 3552683
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV Metoclopramide (1 mg/kg/dose X 5 doses)
Trial: 3552683
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metoclopramide (same schedule) plus Nortriptyline (50 mg PO X 2 doses) plus Thiethylperazine (10 mg IV X 3 doses)
Trial: 27477773
Drug: Statin-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin-based therapy
Trial: 25137523
Drug: Hot saline
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot saline irrigation (HSI) at 49°C, 20 mL every 10 minutes during FESS
Trial: 25137523
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature saline irrigation (RTSI) at 18°C, 20 mL every 10 minutes during FESS
Trial: 23869107
Drug: Butylscopolamine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylscopolamine 20 mg i.v.
Trial: 19115656
Drug: 36 ml
RxNorm normalized name: ALCOHOL 177 mL in 236 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 ml of levobupivacaine 0.1%
Trial: 19115656
Drug: 72 ml
RxNorm normalized name: ethanol 0.72 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 ml of levobupivacaine 0.1%
Trial: 19115656
Drug: 36 ml
RxNorm normalized name: ALCOHOL 177 mL in 236 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 ml of levobupivacaine 0.25%
Trial: 8970819
Drug: Aspirin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3 x 320 mg capsules every 6 h for 3 days, total 3.84 g/day)
Trial: 8509313
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical schedule as aspirin)
Trial: 2868900
Drug: endralazine 5
RxNorm normalized name: hydralazine hydrochloride 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endralazine 5 mg
Trial: 29748932
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 or 1000 mg twice daily for 37 weeks
Trial: 29748932
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in obese adolescents
Trial: 27647769
Drug: AbobotulinumtoxinA (ABO)
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA (ABO) intradermal injection at 1:7 cc dilution (500 unit in 7 cc of NSS)
Trial: 27647769
Drug: AbobotulinumtoxinA (ABO)
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA (ABO) intradermal injection
Trial: 22886431
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment at fluences of 7 J/cm²
Trial: 22886431
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment at fluences of 12 J/cm²
Trial: 22886431
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment at fluences of 20 J/cm²
Trial: 20942239
Drug: Bronchial lavage
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial lavage (BL) with 1% lidocaine (2 ml) and 0.125% metronidazole (5 ml) during bronchoscopic procedure
Trial: 18307585
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (Olanzapine, Risperidone, Haloperidol)
Trial: 12418584
Drug: Post-bronchodilator values
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator values
Trial: 2297337
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug in one eye
Trial: 101843
Drug: Four-drug combination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug combination (hexamethylmelamine, cyclophosphamide, methotrexate, 5-fluorouracil)
Trial: 30761945
Drug: Move-A-Thon (MAT)
RxNorm normalized name: thonzonium
DrugBank: Thonzonium (DB09552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Move-A-Thon (MAT) event with monetized donations to charity, incentivizing participants to achieve a minimum of 3,000 daily steps for 2 weeks.
Trial: 8866933
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 (40 mg for 6 weeks)
Trial: 6509234
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two-hourly toileting for five weeks and environmental changes (Ward B)
Trial: 26667449
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg QD
Trial: 26667449
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg Q-MWF
Trial: 26667449
Drug: Letrozole 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 1.0 mg Q-MWF
Trial: 26667449
Drug: Letrozole 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 0.25 mg Q-MWF
Trial: 26667449
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard dose arm)
Trial: 26667449
Drug: All dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose arms
Trial: 22487197
Drug: Adolescents and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤50 nmol/L in winter/spring
Trial: 22487197
Drug: Adolescents and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤25 nmol/L in winter/spring
Trial: 22487197
Drug: Primary schoolchildren
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary schoolchildren with 25(OH)D levels <50 nmol/L
Trial: 22487197
Drug: Primary schoolchildren
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary schoolchildren with 25(OH)D levels ≤25 nmol/L
Trial: 22487197
Drug: Adolescents and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescents and adults with 25(OH)D levels ≤50 nmol/L in summer/autumn
Trial: 22487197
Drug: Adolescents and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescents and adults with 25(OH)D levels ≤25 nmol/L in summer/autumn
Trial: 20737278
Drug: Local warming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local warming at injection site using an air‐warming device at 40°C for 1 minute prior to injecting 1 ml (10 mg) of rocuronium.
Trial: 20737278
Drug: Local warming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local warming at injection site.
Trial: 18614726
Drug: F+0 (control)
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F+0 (control) - 6 microg Se/L
Trial: 18614726
Drug: F+7 -
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F+7 - 13 microg Se/L
Trial: 18614726
Drug: F+15 -
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F+15 - 21 microg Se/L
Trial: 18614726
Drug: BF -
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BF - breastfed reference group (11 +/- 2 microg Se/L)
Trial: 12368787
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection of a mixture of 0.5 mL (2.5 mg) betamethasone acetate and 3 mL of radiographic contrast material (iotrolan) and 7 mL of 1% lidocaine
Trial: 12368787
Drug: Intradeltoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradeltoid injection
Trial: 7745355
Drug: Ifenprodil tartrate
RxNorm normalized name: ifenprodil tartrate
DrugBank: Ifenprodil (DB08954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifenprodil tartrate (60 mg a.d.)
Trial: 2292326
Drug: sobrerol granules
RxNorm normalized name: sobrerol
DrugBank: Sobrerol (DB13315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sobrerol granules 900 mg/day for up to 10 days
Trial: 29317414
Drug: Virtual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual therapy (VT) for 8 weeks, performing 3-5 upper limb exercises individualized to impairment severity and preference
Trial: 29317414
Drug: Virtual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual therapy (VT) for 8 weeks
Trial: 27440543
Drug: 3.4 g
RxNorm normalized name: psyllium 3.4 g oral wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g PS esters-enriched soy milk powder (2.0 g/d free PS in 30 g soy milk powder)
Trial: 20409444
Drug: Antidepressant continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant continuation
Trial: 10717833
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: 100 mg/m2 i.a. cisplatin followed by 5 day continuous intravenous infusion of 5‐fluorouracil (1 g/m2 per day)
Trial: 10717833
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: i.a. high pressure chemo‐perfusion with 150 mg/m2 cisplatin and simultaneous intravenous infusion of 9 g/m2 sodium thiosulfate
Trial: 7025875
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine (10 mg)
Trial: 19994615
Drug: I-gel Supraglottic
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-gel Supraglottic Airway (IGSA)
Trial: 19994615
Drug: Supreme Laryngeal
RxNorm normalized name: Supreme
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supreme Laryngeal Mask Airway (SLMA) and I-gel Supraglottic Airway (IGSA)
Trial: 17885010
Drug: Soy germ
RxNorm normalized name: soy germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy germ pasta (80-g serving/d)
Trial: 15166388
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg daily for 2 weeks
Trial: 9506196
Drug: ADCON-L gel
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADCON-L gel
Trial: 9479681
Drug: Clinician-Administered Dissociative
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-Administered Dissociative States Scale (CADSS)
Trial: 17034278
Drug: Homeopathic combination
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic combination therapy
Trial: 14647086
Drug: 667 mg
RxNorm normalized name: tryptophan 667 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 667 mg encapsulated sucralose daily for 13 weeks
Trial: 14647086
Drug: Placebo (cellulose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose) capsules daily for 13 weeks
Trial: 8949786
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg once a day for three days
Trial: 8949786
Drug: Pefloxacin 800
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 800 mg once a day for three days
Trial: 2224374
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 mg t.d.s.)
Trial: 30081698
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene 0.1% after fractional CO2 laser treatment
Trial: 30081698
Drug: Topical tioconazole
RxNorm normalized name: tioconazole Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tioconazole 28% after fractional CO2 laser treatment
Trial: 30081698
Drug: KOH test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH test and culture results after treatment in Group A
Trial: 30081698
Drug: KOH test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH test and culture results after treatment in Group B
Trial: 27987182
Drug: Supervised modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised modified step aerobics training (twice weekly, 1 hour per session) over a period of 6 months
Trial: 24727345
Drug: 2-week group-based
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week group-based multicomponent treatment course
Trial: 22410382
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg daily for 4 days)
Trial: 19588641
Drug: Tretinoin microsphere
RxNorm normalized name: tretinoin microsphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin microsphere gel pump 0.04% (TMG PUMP)
Trial: 19588641
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.05% (TAZ)
Trial: 17616006
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg grape seed extract (calculated as proanthocyanidin)
Trial: 17616006
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg grape seed extract (calculated as proanthocyanidin)
Trial: 3675134
Drug: mCPP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCPP (0.5 mg/kg, orally)
Trial: 21915733
Drug: Cefotetan disodium
RxNorm normalized name: Cefotetan Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan disodium 0.5 g
Trial: 21915733
Drug: Cefotetan disodium
RxNorm normalized name: Cefotetan Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan disodium 2.0 g
Trial: 23901678
Drug: Cinitapride 1mg
RxNorm normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinitapride 1mg thrice daily 15 minutes before meals for 4 weeks
Trial: 19968382
Drug: Beginning therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beginning therapy alliance (after Session 1)
Trial: 19968382
Drug: Clients' beginning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clients' beginning therapy process
Trial: 11472271
Drug: Insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogues (general)
Trial: 3115841
Drug: L-lysine monohydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine monohydrochloride (1,000 mg per dose, 3 times a day for 6 months)
Trial: 25039273
Drug: LY3000328 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3000328 (up to 300 mg)
Trial: 22503610
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker + calcium channel blocker
Trial: 22503610
Drug: High-dose angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose angiotensin II receptor blocker (40 mg/d olmesartan)
Trial: 19459794
Drug: MMF(CC) and
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF(CC) and reduced-level calcineurin inhibitor (MMF(CC)/CNI(RL))
Trial: 19459794
Drug: MMF(CC) and
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF(CC) and standard-level CNI (MMF(CC)/CNI(SL))
Trial: 19459794
Drug: fixed-dose MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed-dose MMF and CNI(SL) (MMF(FD)/CNI(SL))
Trial: 11476427
Drug: Subcutaneous fat
RxNorm normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fat increase in girls during puberty
Trial: 11476427
Drug: VO2peak expressed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VO2peak expressed as ml kg(‐1) min(‐1)
Trial: 7932683
Drug: Treatment subjects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment subjects
Trial: 29883885
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous paracetamol every 4 h for 72 h
Trial: 27841759
Drug: Sufficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient vitamin D status (25OHD ≥30 ng/ml)
Trial: 20585969
Drug: Single-dose fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose fosfomycin trometamol (FMT) 3 g
Trial: 20585969
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice a day for 5 days
Trial: 16323126
Drug: Antimalarial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarial treatment (specific regimens not detailed)
Trial: 15456051
Drug: Passive transverse
RxNorm normalized name: TRANSVERSE ROD,STERILE COLOPLAST #2919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive transverse forces (PTF) applied on the deformed body, 4 to 6 treatments lasting 20 minutes each, combined with intensive rehabilitation.
Trial: 15456051
Drug: PTF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTF treatment without additional braces (n=52).
Trial: 7197959
Drug: Urapidil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (2 times 25 mg)
Trial: 7197959
Drug: Phentolamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (2 times 5 mg)